SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.19-4.7%Jan 15 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (10835)3/4/2004 5:43:34 PM
From: IRWIN JAMES FRANKEL  Read Replies (2) of 52153
 
>> One cautionary note pointed out to me by a friend is that they are running a combined Avonex/Antegren trial. So there is a possibility of actually bolstering Avonex use - it will be the only existing drug already studied with Antegren.

In the BIIB CC there seemed to be an acknowledgement that some amount of cannibalization is likely.

I agree with both of those points. The BIIB CC did show some excitement about the acceleration in bringing Antegren forward.

I do know several people already getting treated for MS. My discussions with them suggest that adding an IV infusion to a regular shot would be a non-starter. Some would shift to monthly infusion but even that will take some selling.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News